Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors

24 Mar 2017

Abstract excerpt

Anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients are mostly treated with ALK tyrosine kinase inhibitors (TKIs). Crizotinib is the first generation ALK inhibitor practiced as a primary chemo to combat cancer cells followed by second generation inhibitor ceritinib which are effective against crizotinib resistant ALK mutations. However, patients treated with these drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28332225
DOI: 10.1002/jcb.26004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific InhibitorsPMID 28332225Read ↗

L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.Semantic proximity Read ↗

Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation.Semantic proximity Read ↗

Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs.Semantic proximity Read ↗

Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics.Semantic proximity Read ↗

Exploring the structural and functional impact of the ALK F1174L mutation using bioinformatics approach.Semantic proximity Read ↗

A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.Semantic proximity Read ↗

F1174V mutation alters the ALK active conformation in response to Crizotinib in NSCLC: Insight from molecular simulations.Semantic proximity Read ↗

Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.Semantic proximity Read ↗

Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.Semantic proximity Read ↗

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceSemantic proximity Read ↗

Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.Semantic proximity Read ↗

In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALKL1196M/G1202R mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.